Roopa Dani, MD
Geriatric Medicine · Las Vegas, NVNPI 1063482180
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $455 and has fallen 52.1% since, to $218 in 2025.
Across 98 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$401
- Boehringer Ingelheim$265
- AstraZeneca$233
- Novo Nordisk$215
- Amgen$135
- GSK$122
- plus $436 from 12 others
What the payments were for
- Food & beverage$1,79199%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 19 | $401 |
| Boehringer Ingelheim | 16 | $265 |
| AstraZeneca | 15 | $233 |
| Novo Nordisk | 11 | $215 |
| Amgen | 5 | $135 |
| GSK | 7 | $122 |
| Lilly USA, LLC | 6 | $95 |
| Exact Sciences | 3 | $51 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Astellas Pharma US Inc | 2 | $43 |
| Merck | 2 | $40 |
| Tactile Systems Technology Inc | 2 | $38 |
| Dexcom, Inc. | 2 | $31 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Novartis | 1 | $20 |
| Medtronic | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Johnson & Johnson | 1 | $11 |
How this compares
$1,806 in reported general payments places this provider in the 80th percentile of 36 geriatric medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 64 | $64,759 |
| OzempicSemaglutide | 50 | $60,453 |
| JardianceEmpagliflozin | 25 | $40,200 |
| XareltoRivaroxaban | 19 | $30,600 |
| JanuviaSitagliptin Phosphate | 16 | $27,723 |
| MounjaroTirzepatide | 18 | $18,630 |
| FarxigaDapagliflozin Propanediol | 13 | $16,282 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $14,147 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $10,985 |
| MyrbetriqMirabegron | 13 | $7,887 |
| Atorvastatin Calcium | 677 | $4,842 |
| Levothyroxine Sodium | 403 | $3,298 |
| Rosuvastatin Calcium | 388 | $3,044 |
| SynthroidLevothyroxine Sodium | 33 | $2,760 |
| Gabapentin | 202 | $2,689 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $401 | $66,18986 claims |
| Novo NordiskOzempic | $215 | $60,45350 claims |
| Boehringer IngelheimJardiance | $265 | $40,20025 claims |
| Johnson & JohnsonXarelto | $11 | $30,60019 claims |
| MerckJanuvia | $40 | $27,72316 claims |
| GSKAnoro Ellipta, Breo Ellipta | $122 | $25,13234 claims |
| Lilly USA, LLCMounjaro | $95 | $18,63018 claims |
| AstraZenecaFarxiga | $233 | $16,28213 claims |
| Astellas Pharma US IncMyrbetriq | $43 | $7,88713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 36 geriatric medicine providers in Nevada.
Other geriatric medicine in Las Vegas
- Leonardo Gan-LimLas Vegas$10K
- Syed HussainLas Vegas$2K
- Alvin Bay LinLas Vegas$2K
- Sudheer PolisettyLas Vegas$2K
- Ji YooLas Vegas$1K
- Ajay NellutlaLas Vegas$815
- Anthony ArslanLas Vegas$769
- Mike JeongLas Vegas$60
- Vincent ChuLas Vegas$46
- Roland PuaLas Vegas$43
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.